Diabetes Self-Management Blog

On June 27, the US Food and Drug Administration (FDA) approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes. An FDA advisory panel voted earlier this year in favor of approving Afrezza for the treatment of Type 1 and Type 2 diabetes.

Afrezza, developed by MannKind Corporation, is comprised of an ultrarapid-acting premeal insulin powder and a whistle-size device that the powder is loaded into for inhalation. The insulin, which comes in single-dose cartridges, is administered at the beginning of each meal, “dissolv[ing] rapidly upon inhalation to the deep lung and deliver[ing] insulin quickly to the bloodstream.” Insulin levels peak within 12 to 15 minutes of administration and decline to baseline after roughly 180 minutes.

The safety and effectiveness of Afrezza for treating diabetes was established in two 24-week studies in a total of 3,017 people. In a trial with 1,991 participants with Type 1 diabetes, Afrezza, in combination with long-acting insulin, was found to reduce A1C levels (a measure of blood glucose control over the previous 2–3 months) comparably to the mealtime insulin aspart (brand name NovoLog) in combination with long-acting insulin. And in a trial with 1,991 people with Type 2 diabetes, Afrezza, in combination with oral diabetes medicines, was found to reduce A1C levels to a greater degree than a placebo (inactive treatment) in combination with oral diabetes medicines.

“Today’s approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels,” according to Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research.

The drug label carries a warning stating that acute bronchospasm (tightening of the muscles surrounding the airways) has been observed in people with asthma and chronic obstructive pulmonary disease (COPD) who are using Afrezza. Because of this, the medicine should not be used in those who have a chronic lung disease.

The manufacturer will be conducting several post-marketing trials, including one focusing on the use of Afrezza in children and another evaluating the lung and cardiovascular risk for people using the medicine.

In those with Type 1 diabetes, Afrezza must be used in combination with injected basal (background) insulin. It is not recommended for the treatment of diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body) or in people who smoke.

The most common side effects in people using this medicine are low blood glucose, cough, and throat pain or irritation.

Exubera, an inhalable insulin approved in the United States in 2006, was discontinued by manufacturer Pfizer in 2007. The drug’s high price and bulky inhaler, along with concerns about lung function, led to much lower sales than expected. But according to MannKind, Afrezza is “a very different product, very much a next-generation product,” with an inhaler that is a fraction of the size of the Exubera inhaler.

According to MannKind spokesman Matthew Pfeffer, “our expectation is that [Afrezza] should be priced comparably to current fast-acting insulins delivered in pen form.” It has not yet been determined when Afrezza will hit the market, as MannKind is currently working toward partnering with a pharmaceutical company for distribution of the product.

For more information, see the press releases on the MannKind and FDA websites.


  1. This is great news. I have been an insulin dependent Diabetic since July 1970, 44 years. I am ecstatic and look forward to being on this regiment . when will it be available to local Dr’s ?

    Posted by Karen |
  2. I have type2 and would like to see about using this new product…i am currently using 45mg twice aday with a slow action called Lantus

    Posted by Kenneth Jester |
  3. Yes, I would be interested!!!

    I cannot take any of the medicine by mouth. It tares up my intestines.
    My stomach swells up like a watermelon.

    My legs are swollen… my skin is burning…

    I am tired and desperate. I was diagnosed with
    type 2.

    Posted by Karin Morrison |
  4. Great news! If it doesn’t have to be refrigerated it might finally save money!! Buying needle is expensive for lancets each month.

    Posted by Rebecca Alexander |
  5. I am an insulin dependant diabetic for over 25 years using bo
    th short & long acting and I would love to know more. I would like to see the costs and try it. I have had friends tell me about reading this and hoping I could have it.

    Posted by Sandy James |
  6. As someone with Type 2 diabetes, and who is not able to lower her blood sugar levels with the oral medications,I would be very interested in trying this inhaler.

    How do I contact the manufacturer?

    Posted by Anita Cohen-Williams |
  7. I have type 1 and would love to try this!!!!

    Posted by Tracey Johnson |
  8. I think this is a fabulous addition to the various treatment options for people with type 1 diabetes, especially if it is not heat sensitive. A big concern of mine is the temperature control of my Humalog that I carry with me, particularly living in Florida. Unfortunately I also have asthma and sarcoidosis so I’m going to need to wait for a better option hopefully during my lifetime.

    Posted by Ruth Moore |
  9. I would be very interested in trying this new medicine. Thank you.

    Posted by John Knichel |
  10. Absolutely!!!

    Who wants to stick themselves numerous times a day, if they don’t have to.

    If the inhaler works as well as the pen/syringe, i’m all for it.

    Posted by lourdes |
  11. I would love to use inhaled insulin because the convenience would be totally awesome. It may bring up questions if inhaling in a public restroom though. LoL

    Posted by Diane G |
  12. Yes, I would be willing to try an inhaler for diabetic control. I am currently using Lantus and Humalog.

    Posted by Mike MacKenna |
  13. Yes, I would try it IF the effectiveness is at a level with insulin by pen–and IF the price is in the same field. It’s high time for some new technology in delivering insulin. Thanks.

    Posted by Bob |
  14. I would try this product 100%!
    I have been taking long acting and short acting insulin since the age of 15. I have tried the pump and did not like it , but I do get frustrated some days with having to take another shot. I’ve taken about 24,000 or more shots. I would love to have the option of taking it by mouth. I hope this comes to the market soon with the price availability to most everyone.

    Posted by Kirk J. |
  15. I’d love to have an alturnitave to taking shots. I have taken shots since 1970 and would love an option. Been taking 4 shots/day for the last 16 years or so. Hope this works.

    Posted by Dan |
  16. I would very much want to try this. My doctor said, “when it is finally approve,” he would prescribe it.

    Posted by Joanie S |
  17. I would definitely consider a drug studies this insulin

    Posted by Wayne F Rankin |
  18. I have had type 1 for 44 yrs and luckily am in good shape however after all these years it is getting harder to find injectable places that absorb the insulin well. I would love to have another option!

    Posted by Nicola |
  19. I have been a type 1, since I was 11, maybe even earlier, and I wear a pump close to 20 years. I’ve now cursed my younger son as a type 1, too.
    I’m so heart broken. I cry almost every time I think of it. I’d like Grand children, but, I would hate for that curse to be passed on to his children. I’m now 60 years old!!!
    I was abandoned as a child because my mother could not find it in her heart to give me a injection. I never learned to give myself a proper shot, I still screw the syringe in my body, I hate this illness. I now have MS, I can’t catch a brake. At least my son has something to look forward to.
    Please put this on the fast track, so we can stop suffering.

    Posted by Tanya B. |
  20. I am very interested. Was the side effect of weight gain looked at during the trials? Some of the insulins contribute to weight gain. It would be nice if this didn’t…..

    Posted by Katie |
  21. yes, I think it is great. I use the lantus pen once a day and really like it. I would like the inhaler but I’m sure the price will be staggering. My lantus puts me in the donut hole every year.

    Posted by Joyce |
  22. I would love to stop pricking my fingers.

    Posted by Doris Trader-Moulden |
  23. YESSSSSSSS!!!!!!!

    Posted by Sheli |
  24. I have type 2 diabeties and I am very interested in this product. I am currently on Humolog 3 times a day before each meal and I take Lantus once a day right before bed. I am real curious to see if this can work for me.

    Posted by Araceli Horton |
  25. Sounds wonderful but at what cost? Will medicare approve ?

    Posted by Larry Bonnet |
  26. I am interested in knowing more about inhalable insulin and whether it is appropriate for people who also suffer from asthma.

    Posted by Teri Deimel |
  27. I would definitely be interested in trying. I have type 2 diabetes.

    Posted by Mario Whaley |
  28. yes I am very interested ! I am also interested in the cost and weight gain details . I am tired of sticking myself 7 times a day sometimes more.

    Posted by Patricia Pursel |
  29. I am very interested in trying this insulin.

    Posted by Jim Williams |
  30. Very interested. I live in South America though so may have to wait

    Posted by ester lucia |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.

Insulin & Other Injected Drugs
New Weekly Type 2 Diabetes Drug Approved (09/26/14)
Dispelling the Myths of Insulin Therapy (08/01/14)
Insulin for Type 2 (07/14/14)

Diabetes News
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
FDA Approves Remote Glucose-Monitoring Technology (10/24/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)

Diane Fennell
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
FDA Approves Remote Glucose-Monitoring Technology (10/24/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.